Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis

Invasive Fusariosis Clinical Trial

Official title:

Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04982159
• Other study ID #: FIB-VOR-2019-01
• Status: Completed
• Start date: January 1, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: May 2022
• Source: Maimónides Biomedical Research Institute of Córdoba
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Multi-centered, international, observational and retrospective study to analyze the correlation between MIC and clinical outcome in patients with invasive fusariosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Invasive fusariosis diagnostic

• Proof of anti-fungic susceptibility according to EUCAST or CLSI, for the medicine used in the treatment of invasive fusariosis.

• Available data about anti-fungic medicines used: name of medicine, start and end date of treatment.

• Available information about clinical outcome of illness after 30 days, 6 weeks and 90 days (dead or alive).

• Only cases of invasive fusariosis proven or possible will be included.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Fusariosis
• Invasive Fusariosis

Intervention

Other:
• There is no intervention. This is an observational study.
There is no intervention. This is an observational study.

Locations

Country	Name	City	State
Spain	Hospital Universitario Reina Sofía	Córdoba

Sponsors (1)

Lead Sponsor	Collaborator
Maimónides Biomedical Research Institute of Córdoba

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Evolution	Retrospective evaluation of death rate.	6 weeks after diagnosis

External Links

•   Link to article with the results of the whole trial.